胃癌患者腹腔内或原发灶癌细胞的活性和去活性的研究

STUDY ON VIABILITY AND DEVIABILITY OF CANCER CELLS FROM PERITONEAL CAVITY OR PRIMARY FOCUS IN PATIENTS WITH GASTRIC CANCER

本文共收集胃癌患者78例,对其中的50例(4例早期胃癌)用腹腔冲洗、台盼兰染色、酶学染色和放射自显影术行腹腔内游离癌细胞的检出率及其活性的研究,而对另外28例胃癌原发灶的癌细胞,应用体外短期培养及液闪技术行去活性研究(药敏试验)。其结果腹腔内游离癌细胞的检出率为44.0％,且与胃癌组织类型及胃癌浆膜浸润程度和浸润面积等因素明显相关,多数腹腔内游离癌细胞具有高度活性。MMC、ADM、5-Fu、PDD和E1-AI对原发灶胃癌细胞的抑制率分别为14.3％,21.4％、28.6％,14.3％和32.5％,EL-AI对其抑制率较高,但同其它药物相比无显著差异(P>0.05)。

Our investigation was carried on 78 gastric cancer patients with 4 early stage cases only. The detection rate and viability of the peritoneal free cancer cells from 50 cases among which were examined by peritoneal lavage with trypan blue and enzymologic staining and ~3H-TdR uptake. And the same was done in another 28 cases by a piece of tumor mass taken from the primary focus during operation. After a short period of culture in vitro, 5 kinds of antitumor drugs were used for examination with ~3H-TdR uptake scintillation count to estimate their deviability effects. The following results were found: Among 50 cases, the detection rate of peritoneal free cancer cells was 44.0％. It was well correlated to the histopathological typing and the degree and the area of serosal invasion. The inhibition rate of 28 cases by MMC, ADM, 5-Fu, PDD and EL-AI (β-elemene)to the cancer cells of primary focus were 14.3％, 21.4％, 28.6％, 14.3％ and 32.5％ respectively. The inhibition rate of EL-AI is higher than that of others.